We analyzed the incidence of neurological complications in 77 patients receiving stem cell transplantation (SCT), and 12 patients (15.8%) had the following symptoms: convulsions, intracranial hemorrhage, and leukoencephalopathy. Although statistically not significant, neurological complications were seen more frequently in patients after allogeneic transplantation, and in those with acute graft-versus-host disease (GVHD) exceeding grade II. The most significant risk factor for neurological complications was identified as unrelated donor allogenic transplantation (P = 0.016). Complications were categorized into three groups, based on time of onset and symptoms: (1) convulsions during the conditioning period, (2) intracranial hemorrhage during the period of granulocyte recovery, and (3) leukoencephalopathy at around 2 months after SCT. We propose awareness of the risks of neurological complications in each period after SCT so that immediate and effective treatment of patients can be instigated.
patients from HLA-identical related donors, 12 from HLAidentical unrelated donors, and 23 from autologous marrow or peripheral blood stem cells. All of these patients were included in this study. Mean age was 9.0 years (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Indications for transplantation were acute lymphoblastic leukemia in 31 patients (14 in first complete remission: 1CR), acute myelogenous leukemia in 14 (nine in 1CR), aplastic anemia in nine, non-Hodgkin's lymphoma in seven, myelodysplastic syndrome in four, rhabdomyosarcoma in three, Wiscott-Aldrich syndrome in three, chronic myelogenous leukemia in two, juvenile chronic myelogenous leukemia, neuroblastoma, fibrosarcoma, and yolk sac tumor in one each. Fifty-nine patients received intrathecal methotrexate (MTX) and cytarabine (AraC), and five received cranial irradiation (20) (21) (22) (23) (24) as central nervous system (CNS) prophylaxis before transplantation. We conducted careful neurological examinations according to the protocol of Hokkaido University School of Medicine Department of Pediatrics. This included: (1) mental status with state of consciousness, emotional reaction, and memory, (2) speech, (3) praxis, (4) gnosia, (5) cranial nerve signs (6) motor and sensory system, (7) coordination, (8) gait and posture, (9) reflexes. All signs were considered relative to the patients' age.
Conditioning regimen and GVHD prophylaxis
Conditioning regimens consisted of cyclophosphamide (CY) or melphalan (L-PAM), etoposide (VP-16) or AraC, and total body irradiation (TBI) in 39 patients. Busulfan (BU), and CY or L-PAM with or without VP-16 were administered in 28 patients, total lymphoid irradiation and CY in five patients, carboplatin, VP-16, and L-PAM in five patients, ranimustine, VP-16, AraC, and CY in five patients.
Sixteen patients received prophylaxis against GVHD with antithymocyte globulin (ATG). Forty-seven patients received prophylaxis against GVHD with cyclosporine A (CsA) in combination with MTX according to the Seattle schedule, 1 four patients received CsA alone, two patients received MTX alone, and one patient received tacrolimus (FK506) alone.
Supportive care
Antibacterial and antifungal prophylaxis was with oral polymixin B and amphotericin B, inhaled vancomycin, tobracin and amphotericin B. Antiviral prophylaxis was with oral acyclovir from day −7 to day +35 and weekly intravenous anti-cytomegalovirus (CMV) high titer ␥-globulin from day −6 to day +90. Granulocyte colony-stimulating factor (G-CSF) was given intravenously at 5 g/kg from day +5 to engraftment, defined as an absolute neutrophil count of Ͼ500/l for 3 consecutive days. Oral mucositis was treated with intravenous pentazocine and parental nutrition.
Acute GVHD was diagnosed and graded according to the Seattle criteria.
2 Treatment of acute GVHD was with prednisolone, methylprednisolone, CsA and/or FK506. Hepatic veno-occlusive disease (VOD) was diagnosed and graded according to McDonald et al's criteria. 3 CMV infection was diagnosed in the presence of positive CMV antigenemia.
Statistical analysis
Statistical comparisons were completed using the chisquare test for independence or Fisher's exact probability test. Survival rates were calculated using the Kaplan-Meier method and the Wilcoxon rank-sum test. The test is performed at the 5% level of significance.
Results

Characteristics of the patients
Among the 77 patients, 12 patients (15.8%) developed neurological symptoms including intracranial hemorrhage, seizures, cerebellar ataxia, oculomotor paralysis and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Table 1 summarizes patient characteristics, which were divided into two categories: one comprising patients with neurological events and the other those without events. The clinical episodes and treatments given to patients with neurological events are summarized in Table 2 .
Possible regimen-related toxicities
Four patients developed seizures during conditioning, on days −9, −3, −9 and −5 in cases 1, 2, 4 and 11, respectively. These patients showed no abnormal findings on cerebral computed tomography (CT) scans, and on cerebrospinal fluid examination. They recovered without any residual neurological abnormalities, but two of them subsequently died from VOD and relapse. Two patients, cases 7 and 12, developed leukoencephalopathy due to CsA and FK506, on day +53 and +50, respectively. They had sudden convulsions and showed high intensity areas in the subcortical white matter and cortex in the occipital region on cerebral magnetic resonance imaging (MRI) (T2-weighted images). Following cessation of the drugs, their clinical condition improved and finally recovered with no remaining neurological or MRI abnormalities. Leukoencephalopathy probably associated with the conditioning regimen was seen in two patients, on days +67 and +263 in case 5 and 8, respectively. Initial symptoms consisted of generalized seizures (case 8) and cerebellar ataxia (case 5). Their cerebral MRI (T2-weighted images) showed high intensity areas in the subcortical white matter, and brain atrophy. One patient 4 (36.4%)*** 5 (11.6%)*** *P = 007, **P = 0.016, ***P = 0.09. ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; JCML = juvenile chronic myelogenous leukemia; CML = chronic myelogenous leukemia; MDS = myelodysplastic syndrome; NHL = nonHodgkin's lymphoma; RMS = rhabdomyosarcoma; Nbl = neuroblastoma; AA = aplastic anemia; WAS = Wiskott-Aldrich syndrome; GVHD = graftversus-host disease; CR = complete remission; CP = chronic phase.
(case 5) received hyperbaric oxygen therapy and recovered without clinical sequelae. Although the clinical symptoms in the latter two patients resolved, abnormal MRI findings persisted in one patient (case 8).
Cerebrovascular complications
Three patients, cases 3, 10 and 6, developed intracranial hemorrhages on days +18, +19 and +64, respectively. One patient (case 6) with extensive acute GVHD developed sudden oculomotor nerve paralysis on day +64, and cerebral CT scan demonstrated bleeding in the pons. The platelet count was 2.1 ϫ 10 4 /l. He died on day +82 due to severe acute GVHD (grade IV). The other two patients, cases 3 and 10, developed sudden generalized seizures and anisocoria during hematological recovery following SCT, and both died on day +19. Platelet counts were 4.4 ϫ 10 4 /l in case 3 and 5 ϫ 10 4 /l in case 10, and no coagulation abnormalities or platelet transfusion refractoriness was present in either case. 
Other episodes
One patient (case 9) developed headache and vomiting on day +60. He had a serum sodium of 118 mEq/l and a plasma antidiuretic hormone of 4.3 pg/ml, and was diagnosed as having inappropriate antidiuretic hormone secretion (SIADH). He recovered by a conventional supportive care without remaining any neurological abnormalities.
No patients with neurological complications had abnormal levels of trace elements, vitamin B1, or hyperammonemia. Lumber punctures were performed in all patients with neurological complications, except for cases 3, 6 and 10, and human herpes virus 6 gene was negative in all as determined by polymerase chain reaction.
Occurrence of neurological complications during SCT
In Figure 1 , onsets of neurological events as seen in each patient are depicted relative to the time-course of SCT. Occurrence of neurological complications could be categorized into three groups on the basis of time of onset and symptoms: (1) convulsions during the conditioning regimen, (2) intracranial hemorrhage during hematological recovery, and (3) leukoencephalopathy at around 2 months after SCT.
Prognosis
Two of the seven patients with relapse-free survivals suffered from chronic GVHD, but neither had neurological sequelae. Comparison of overall survival by Kaplan-Meier method showed no significant differences between patients with neurological events and those without (Figure 2 , P = 0.15). However, when the comparison was confined to the early period after SCT, it seemed that the adverse neurological events contributed to early death. No significant differences were observed between patients with neurological events and those without such events in terms of age, sex, irradiation during conditioning, disease (malignant or nonmalignant), grade of acute GVHD, and remission (1 CR or м2 CR). However, neurological complications tended to be seen more frequently in patients with acute GVHD of over grade II (P = 0.09), and those receiving allogeneic transplants (P = 0.07). An apparently significant difference was also observed after unrelated donor allogeneic transplantation (P = 0.016) ( Table 1) .
Discussion
The major problems in the post-SCT period were toxicity from radiation therapy and/or chemotherapy, infection caused by immunosuppression and neutropenia, thrombocytepenia, mucosal injury, VOD due to endothelium injury, GVHD, and disease relapse. The effects of the above on the nervous system have been reported in previous studies. [4] [5] [6] [7] [8] [9] [10] [11] However, little has been reported on the analysis of risk factors for neurological complications. We found in the present study that a significant variable relating to neurological complications in SCT recipients was unrelated donor allogeneic transplantation. Although statically not significant, neurological complications were seen more frequently in patients receiving allogeneic transplants, and those with acute GVHD exceeding grade II. In patients receiving allogeneic transplants, inevitable problems relate to control of GVHD with the use of immunosuppressive agents. Immunosuppressive agents, such as CsA, FK506, prednisolone, and methylprednisolone are the drugs of choice for GVHD, and antiviral agents, such as ganciclovir and acyclovir, are requisite for the treatment of herpetic viral infections. All of these drugs are reported to be harmful to the CNS. [12] [13] [14] [15] [16] [17] Fifteen patients were proven to have CMV infection although not involving the CNS, and all of them were treated with ganciclovir without experiencing neurological side-effects. However, it has been reported that patients with severe GVHD tend to experience not only CNS toxicity secondary to immunosuppressive drugs, but also CNS infections due to immunosuppression. [18] [19] [20] In this context, we should be aware that patients receiving unrelated donor allogeneic transplants are at significant risk of severe neurological events.
The occurrence of neurological complications during the course of SCT seems to fall into three categories based on the time of onset of symptoms as shown in Figure 1 . There are three critical periods: (1) during conditioning, (2) during hematological recovery and (3) at around 2 months after SCT.
Drugs and radiation administered during conditioning may cause or contribute to CNS dysfunction. [4] [5] [6] [7] [8] [9] [10] [11] 21 It has been reported that BU is associated with generalized seizures, and prophylaxis with antiepileptic drugs is recommended for patients receiving the drug. 22, 23 In the present study, patients receiving BU as part of their conditioning were given prophylaxis with 5 mg/kg phenytoin intravenously 12 h before the initial administration of BU and subsequently with 2.5 mg/kg phenytoin orally every 12 h until 1 day after finishing BU. However, two patients (cases 2 and 11) developed generalized seizure despite phenytoin prophylaxis. We have previously reported that patients receiving BU can show electroencephalogram (EEG) abnormalities without having clinical symptoms, 24 especially older children. Therefore, it may be necessary to monitor the serum concentration of BU and administer antiepileptics during the conditioning.
Three patients developed intracranial hemorrhage, on days +18, +19 and +64. In two patients with intracranial hemorrhage on days +18 (case 10) and +19 (case 3), the bleeding coincided with the recovery of granulocytes. Platelet counts were 4.4 ϫ 10 4 /l and 5.0 ϫ 10 4 /l in case 10 and 3, respectively, and no coagulation abnormalities or platelet transfusion refractoriness were present. The cause of these episodes remains unclear, but hemorrhage during this period may relate to endothelial injury, possibly from the conditioning therapy, acute GVHD, and/or neutrophil activation by G-CSF. Comparison of overall survival by the Kaplan-Meier method (Figure 2) showed that adverse neurological events apparently contributed to early death following SCT. Therefore, in the SCT setting, it is important to pay much attention to hemorrhage in the immediate post-SCT period.
In our study, five patients had developed neurological complications including leukoencephalopathy in three patients at about 2 months after SCT. While leukoencephalopathy is one of the most serious complications in patients receiving SCT and can cause mental and/or growth retardation, epilepsy, ataxia, and paralysis, [4] [5] [6] [7] [8] [9] no patients with leukoencephalopathy in our study had clinical sequelae. One patient (case 5) who developed cerebellar ataxia received hyperbaric oxygen therapy and recovered without clinical sequelae. Leukoencephalopathy caused by CsA or FK506 has been reported in previous studies, but little information was given concerning onset of symptoms and localization of brain lesions. In two patients with leukoencephalopathy, one on CsA and the other FK506, both developed a sudden convulsion at about 2 months after SCT with a high intensity area in the occipital lobe on MRI (T2-weighted images).
We conclude that in patients receiving SCT, a significant risk factor for neurological complications is unrelated donor allogeneic transplant, and we found a tendency towards neurological complications contributing to early death following SCT. We propose that patients undergoing SCT should be followed carefully particularly with regard to risk of neurological complications at each period during the course of SCT.
